Domestic special oral drug approved, two tablets are effective

A domestically produced oral drug with special effects has been approved and can be effective in two pills.

A domestically produced oral drug with special effects has been approved and can be effective in two pills. VV116, a small molecule drug for the treatment of COVID-19, has entered the domestic market Clinical trial stage. The small molecule drug VV116 is being promoted in the domestic market. The domestically produced special oral drug has been approved and is effective in two tablets. Domestic special oral drug has been approved, two tablets can be effective1

According to media reports, there is good news in China. VV116, a special drug developed by China to fight the new coronavirus, has been approved for marketing. It should be taken orally. Being able to have a therapeutic effect means that the world is expected to end the raging new coronavirus epidemic.

The new coronavirus has swept the world

It has been two years since the outbreak of the new coronavirus. As time goes by, the new coronavirus has not disappeared on its own as people originally expected. Instead, it has intensified and even mutated into multiple strains, among which the Omicron strain is the most popular one now.

Under the terror of Omicron, China has gradually brought the domestic epidemic under control by relying on its institutional advantages. But not all countries are as lucky as China. Under the offensive of the new coronavirus, the number of people who have died from the new coronavirus in the United States has exceeded 930,000, and the number of confirmed cases in some countries in a single day has exceeded 100,000.

China has developed special drugs

After stabilizing the domestic epidemic, our country has been developing special drugs. Through the unremitting efforts of scientific researchers, China has developed VV116, a specific drug to combat COVID-19. According to clinical data, obvious effects can be seen after taking two tablets. Now, this specific drug has been approved by the government for marketing in Uzbekistan. Compared with previous large molecule drugs, the specific drugs developed this time are small molecule oral drugs. The advantage of this special medicine is not only to save production costs, but also to facilitate transportation and storage. This means that the era of the new coronavirus is expected to end.

The oral drug VV116 has a significant effect

Before the advent of VV116, the most effective one in fighting the new coronavirus was remdesivir. Its working principle is to destroy the replication of the virus to curb the spread of the virus. However, after evaluation, Remdesivir can also cause serious side effects to the host while fighting the virus. VV116 was inspired by Remdesivir and was improved on the basis of Remdesivir to solve the side effects of the drug. VV116 can also be taken orally, allowing the drug to take effect quickly in the body. In clinical trials, researchers applied VV116 to mice infected with the virus, which significantly improved the pathological changes in lung tissue.

In fact, most of the people diagnosed with COVID-19 are mildly or moderately infected. If they can cure COVID-19 by taking VV116 orally like a cold, it will be of great significance to global epidemic prevention and control. You should know that oral medications can reduce the risk of infection while saving medical costs. In addition to the development of VV116, other oral drugs in the development process in China are also expected to be launched. It must be said that the remarkable effect of VV116 has given people struggling with the new coronavirus a glimmer of hope. Domestic special-effect oral drugs have been approved, and two pills are effective 2

The People’s Daily Health Client sorted out and summarized the drugs that have been approved for marketing, emergency use, or are about to be launched, and found that since November 2021, the People’s Daily Health Client , new crown oral drugs continue to come to the forefront.

First, Merck & Co.’s Molnupiravir and Pfizer’s Paxlovid were approved for marketing or emergency use; followed closely, my country’s original COVID-19 oral drug VV116 also relied on its excellent Based on clinical trial data, it was approved for marketing in Uzbekistan not long ago.

Now Japan’s domestically produced COVID-19 oral drug is also considered to be launched in the country. If this oral drug is approved for marketing, it will supply medicine to 1 million people by the end of March, and it plans to start increasing production in April. 10 million people provided medicine.

On January 21, people wearing masks walked on the streets of Shibuya, Tokyo, Japan.

Picture according to Xinhua News Agency

Japan’s new coronavirus oral drug S-217622: may be approved for marketing as early as spring

This anti-new crown oral drug named “S-217622” is currently under development Mid-stage clinical trials. In its Phase II and III clinical trials, asymptomatic and mildly infected people who took the drug had a decrease in COVID-19 viral load by approximately 63% to 80% after four days compared with a control group that took a placebo. The company said the oral drug is also effective against the mutated Omicron strain of the new coronavirus.

Infected patients will be tested, and global clinical trials will begin at the end of February. If this oral drug is approved for marketing, Shionogi will be able to supply the drug to 1 million people by the end of March, and plans to start in April. Significantly increase production in one fiscal year, supplying medicine to 10 million people. ”

China’s new coronavirus oral drug VV116: expected to be launched in the country in the second half of the year

Developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, my country. The COVID-19 treatment small molecule drug VV116, jointly developed by the Wuhan Institute of Virology of the Academy of Sciences, the Xinjiang Institute of Physics and Chemistry Technology of the Chinese Academy of Sciences, and the Central Asian Drug Research and Development Center of the Chinese Academy of Sciences, has entered the clinical trial stage in China.

CCTV News reported that preclinical pharmacodynamic studies show that VV116 has significant inhibitory activity in vitro against the original strain and mutant strains of the new coronavirus, such as Delta virus. The scientific research team of researcher Shen Jingshan of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and collaborating scientific research institutions found through experiments on adenovirus mouse models that oral administration of VV116 can reduce the virus titer below the detection limit, and can significantly improve the pathological changes in the lung tissue of experimental model animals. A series of preclinical safety evaluation experiments showed that VV116 has good safety and no genotoxicity.

The small molecule drug VV116 is in the process of being launched in China (expected in the second half of the year). Previously, this drug had been authorized for emergency use in Uzbekistan.

Two oral COVID-19 drugs have been authorized for use in the United States

On December 23, according to the U.S. Food and Drug Administration (FDA), the U.S. Food and Drug Administration The Drug Administration (FDA) authorized Merck’s antiviral drug (Molnupiravir) Monupivir for the treatment of COVID-19; in addition, on December 22, the U.S. FDA authorized Pfizer’s COVID-19 antiviral drug Paxlovid, which is the U.S. The first antiviral Covid-19 pill approved to be taken at home before patients become ill and hospitalized.

Both drugs reduce the risk of hospitalization and death in people diagnosed with the COVID-19 virus and at risk of developing severe cases of the disease. Recent preclinical evidence suggests that Molnupiravir has antiviral activity against Omicron. Paxlovid was 89% effective in preventing hospitalization and death in patients at high risk for severe disease.

In addition to the United States, the Israeli Ministry of Health issued a statement on December 26, 2021, stating that the ministry had approved the emergency use of Paxlovid, an oral drug for the treatment of COVID-19 produced by Pfizer of the United States. Domestic special-effect oral drug has been approved, two tablets are effective3

Since the outbreak of the new coronavirus in 2020, the world has been fighting the epidemic for more than two years, and the epidemic continues to rage, from the original new coronavirus to the Delta mutant virus strains, and then to the Omicron mutated virus, the road to fighting the epidemic is long and arduous. It is worth mentioning that according to The Paper, China’s first oral COVID-19 drug, VV116, is expected to apply for listing in the second half of the year.

Breaking news from China

Since the outbreak of the new coronavirus, China has mobilized the whole country to fight against the epidemic and responded with extraordinary measures. We controlled the spread of the virus in a short period of time and delivered an answer sheet that was almost perfect. The COVID-19 vaccine developed by China is also at the forefront of the world, and the international community has high hopes for China.

As China’s Sinovac and Sinopharm vaccines are being accepted by the world, China announced major good news, that is, my country’s original COVID-19 small molecule oral drug VV116 has been approved for marketing in Uzbekistan.

It is reported that compared with large molecule drugs, small molecule oral drugs have more significant antiviral effects, lower production costs and medication costs, and are also very convenient for storage and transportation.

The specific medicine can be effective after taking two tablets orally. Does this mean that the new coronavirus epidemic is finally over? The use of small molecule oral drugs can quickly eliminate the virus and minimize the risk of spreading the virus, which is more beneficial to global epidemic prevention and control. The new coronavirus oral drug developed by a Chinese company is another new coronavirus oral drug approved for marketing after Merck and Pfizer’s new coronavirus oral drugs were approved.

Actively fight the epidemic and do not take it lightly

After the outbreak, China has been united to fight against the new coronavirus and strive to achieve an early victory in the fight against the epidemic. However, in the face of a global health crisis and a pandemic, China's efforts alone are far from enough. Countries around the world must also join the anti-epidemic team, rather than emphasizing so-called "herd immunity."

Currently, the United States is still the hardest hit area by the global epidemic, proving that the "herd immunity" advocated by Western countries is unreliable and will only make more people infected with the new coronavirus. Herd immunity should be established through reasonable channels, such as comprehensive vaccination against COVID-19, rather than through infection with the virus to produce antibodies in the body. This is tantamount to making fun of human life.

No country can stay out of the COVID-19 epidemic. We hope that Western countries can face up to the epidemic, learn from China's anti-epidemic experience, and work hard to fight the epidemic, instead of letting it go and becoming "accomplices" of the new coronavirus. If efforts are not made to fight the epidemic, no matter how many specific drugs are developed, it will be difficult to control the epidemic.